VariZIG for prophylaxis after exposure to varicella

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1241-1242, 2006, Pages 69-70

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; GENERIC DRUG; HERPES ZOSTER IMMUNOGLOBULIN; RHESUS D ANTIBODY; ANTISERUM; VARICELLA ZOSTER IMMUNE GLOBULIN; VARICELLA-ZOSTER IMMUNE GLOBULIN;

CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG SAFETY; FATIGUE; FLUSHING; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION RATE; INJECTION SITE PAIN; MYALGIA; NAUSEA; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; RIGOR; SHORT SURVEY; SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS TRANSMISSION; ARTICLE; DRUG APPROVAL; FEMALE; INFANT; NEWBORN; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PREGNANCY; PREMATURITY; RISK FACTOR;

CHICKENPOX; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INVESTIGATIONAL NEW DRUG APPLICATION; PRACTICE GUIDELINES; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33749359513     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.
2. Centers for Disease Control and Prevention (CDC). Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48 (RR-6):1.
3. G Koren et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42:267.